表紙
市場調査レポート

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.:製品パイプライン分析

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 314194
出版日 ページ情報 英文 37 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.95円で換算しております。
Back to Top
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.:製品パイプライン分析 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Product Pipeline Review - 2015
出版日: 2015年08月31日 ページ情報: 英文 37 Pages
概要

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. は生物医薬品を研究、開発、製造、および製品化しています。その製品には、遺伝子工学薬、光線力学療法薬、リポゾーム薬、医療用診断製品などがあります。

当レポートでは、Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.の基本情報

  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.の概要
  • 主要情報
  • 企業情報

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.:R&Dの概要

  • 主な治療範囲

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品
  • パートナー製品
    • パートナー製品/併用療法モダリティ

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.:パイプライン製品の概況

  • 治験段階にあるパイプライン製品
    • 第II相にある製品/併用療法モダリティ
    • 第I相にある製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階にある製品/併用療法モダリティ
    • 創薬中の製品/併用療法モダリティ

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.:薬剤プロファイル

  • rhLT28-171
  • Hitenercept
  • rhPTH 1-34
  • vincristine sulfate liposomal
  • Fderceptin
  • Nifeviroc

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.:パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.:最近のパイプライン動向

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.:開発が中止されたパイプライン製品

  • 開発が中止されたパイプライン製品のプロファイル
    • Nifeviroc

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.:本社と子会社の所在地

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07534CDB

Summary

Global Markets Direct's, 'Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Product Pipeline Review - 2015', provides an overview of the Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.'s pipeline products

Reasons to buy

  • Evaluate Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Snapshot
    • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Overview
    • Key Information
    • Key Facts
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Research and Development Overview
    • Key Therapeutic Areas
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline Products Glance
    • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Early Stage Pipeline Products
      • IND/CTA Filed Products/Combination Treatment Modalities
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Drug Profiles
    • aminolevulinic acid hydrochloride
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Hitenercept
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Protein to Agonize PTH Receptor for Osteoporosis and Osteoarthritis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • T-0001
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • vincristine sulfate
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Fderceptin
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody Conjugate to Inhibit CD30 for Solid Tumor
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit Sclerostin for Osteoporosis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • paclitaxel
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PCSK-9
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Nifeviroc
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline Analysis
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline Products by Target
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline Products by Route of Administration
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline Products by Molecule Type
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Dormant Projects
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • Nifeviroc
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., Key Information
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., Key Facts
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline by Indication, 2015
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline by Stage of Development, 2015
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Monotherapy Products in Pipeline, 2015
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Partnered Products in Pipeline, 2015
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Partnered Products/ Combination Treatment Modalities, 2015
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Phase II, 2015
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Phase I, 2015
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - IND/CTA Filed, 2015
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Preclinical, 2015
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Discovery, 2015
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline by Target, 2015
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline by Route of Administration, 2015
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline by Molecule Type, 2015
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action, 2015
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Dormant Developmental Projects,2015
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Discontinued Pipeline Products, 2015

List of Figures

  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline by Top 10 Indication, 2015
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline by Stage of Development, 2015
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Monotherapy Products in Pipeline, 2015
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline by Top 10 Target, 2015
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline by Top 10 Route of Administration, 2015
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline by Top 10 Molecule Type, 2015
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top